propafenone has been researched along with Shock, Septic in 5 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
Shock, Septic: Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The trial includes septic shock patients with new-onset arrhythmia, but without severe impairment of the left ventricular ejection fraction." | 2.90 | Efficacy and safety of 1C class antiarrhythmic agent (propafenone) for supraventricular arrhythmias in septic shock compared to amiodarone: protocol of a prospective randomised double-blind study. ( Balik, M; Brestovansky, P; Brozek, T; Duska, F; Flaksa, M; Maly, M; Matousek, V; Otahal, M; Pazout, J; Porizka, M; Rulisek, J; Sachl, R; Smid, O; Stach, Z; Stritesky, M; Svobodova, E; Waldauf, P, 2019) |
| " Except for the dosage of noradrenaline (0." | 1.46 | Propafenone for supraventricular arrhythmias in septic shock-Comparison to amiodarone and metoprolol. ( Balik, M; Kolnikova, I; Kristof, J; Maly, M; Tavazzi, G; Waldauf, P, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balik, M | 4 |
| Maly, M | 4 |
| Brozek, T | 3 |
| Rulisek, J | 2 |
| Porizka, M | 2 |
| Sachl, R | 2 |
| Otahal, M | 2 |
| Brestovansky, P | 3 |
| Svobodova, E | 2 |
| Flaksa, M | 2 |
| Stach, Z | 2 |
| Horejsek, J | 1 |
| Volny, L | 1 |
| Jurisinova, I | 1 |
| Novotny, A | 1 |
| Trachta, P | 1 |
| Kunstyr, J | 1 |
| Kopecky, P | 1 |
| Tencer, T | 1 |
| Pazout, J | 2 |
| Belohlavek, J | 1 |
| Duska, F | 2 |
| Krajcova, A | 1 |
| Waldauf, P | 3 |
| Matousek, V | 1 |
| Smid, O | 1 |
| Stritesky, M | 1 |
| Kolnikova, I | 1 |
| Tavazzi, G | 1 |
| Kristof, J | 1 |
| Khoury, J | 1 |
| Azzam, ZS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Randomized Study of Efficacy and Safety of 1c Class Antiarrhythmic Agent (Propafenone) in Septic Shock[NCT03029169] | Phase 4 | 210 participants (Actual) | Interventional | 2017-10-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for propafenone and Shock, Septic
| Article | Year |
|---|---|
Propafenone versus amiodarone for supraventricular arrhythmias in septic shock: a randomised controlled trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Propafenone; Prospective Studies; S | 2023 |
Efficacy and safety of 1C class antiarrhythmic agent (propafenone) for supraventricular arrhythmias in septic shock compared to amiodarone: protocol of a prospective randomised double-blind study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Double-Blind Method; | 2019 |
3 other studies available for propafenone and Shock, Septic
| Article | Year |
|---|---|
Propafenone for supraventricular arrhythmias in septic shock-Comparison to amiodarone and metoprolol.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Critical Care; Electric Countershock; Female; Humans; Male | 2017 |
Reply.
Topics: Amiodarone; Arrhythmias, Cardiac; Humans; Metoprolol; Propafenone; Shock, Septic | 2018 |
Propafenone for supraventricular arrhythmias in septic shock-Comparison to amiodarone and metoprolol.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Metoprolol; Propafenone; Shock, Se | 2018 |